Figure 7.

Schematic representation of protection conferred by the dLNs-targeting ABD-VP1 vaccine against CVB3-induced viral myocarditis. By forming complexes with albumins, ABD-VP1 vaccine possessed a longer serum half-life and the dLNs-targeting ability. It efficiently recruited and promoted the maturation of DCs, and elicited more robust CVB3-specific T cell immune responses as well as a higher level of serum neutralizing antibodies. Accordingly, ABD-VP1 vaccine provided enhanced immunoprotection against CVB3-induced myocarditis compared with the original VP1 vaccine.